Chen Xi, Wu Jianzhang, Wang Jiabing
School of Medical College, Taizhou University, Taizhou, Jiaojiang, Zhejiang, China.
School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
Front Oncol. 2022 Nov 29;12:1013544. doi: 10.3389/fonc.2022.1013544. eCollection 2022.
Non-small cell lung cancer (NSCLC) has become one of the most common malignant tumors. Emerging evidence has shown that tumor resistance to apoptosis by damaging or bypassing apoptotic cell death is a major contributor to poor responses to therapy in patients with NSCLC. Pyroptosis is a new type of cytolytic and inflammatory programmed death distinct from apoptosis. Currently, pyroptosis has been reported to cause a strong inflammatory response and significant tumor suppression. It is considered a promising therapeutic strategy and prognosis for NSCLC. In this review, we summarized the characteristics of pyroptosis from its underlying basis and role in NSCLC, thereby providing the potential of pyroptosis as a therapeutic strategy and highlighting the challenges of activating pyroptosis in NSCLC treatment.
非小细胞肺癌(NSCLC)已成为最常见的恶性肿瘤之一。新出现的证据表明,肿瘤通过破坏或绕过凋亡性细胞死亡来抵抗凋亡,是NSCLC患者治疗反应不佳的主要原因。细胞焦亡是一种不同于凋亡的新型溶细胞性和炎症性程序性死亡。目前,据报道细胞焦亡会引发强烈的炎症反应并具有显著的肿瘤抑制作用。它被认为是NSCLC一种有前景的治疗策略和预后指标。在本综述中,我们从其潜在机制和在NSCLC中的作用总结了细胞焦亡的特征,从而提供了细胞焦亡作为一种治疗策略的潜力,并强调了在NSCLC治疗中激活细胞焦亡的挑战。